143 related articles for article (PubMed ID: 37317885)
21. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
Offin M; Shaverdian N; Rimner A; Lobaugh S; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Lee N; Kris MG; Rudin CM; Zhang Z; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Aug; 149():205-211. PubMed ID: 32361014
[TBL] [Abstract][Full Text] [Related]
22. Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non-small-cell lung cancer after definitive chemoradiotherapy.
Sakaguchi T; Ito K; Furuya N; Morikawa K; Fujiwara K; Nishii Y; Inoue T; Hataji O; Mineshita M
Thorac Cancer; 2021 Jul; 12(13):2024-2030. PubMed ID: 34002492
[TBL] [Abstract][Full Text] [Related]
23. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
Shaverdian N; Offin MD; Rimner A; Shepherd AF; Wu AJ; Rudin CM; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Mar; 144():101-104. PubMed ID: 31786421
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
Hussain S; Klugarova J; Klugar M
Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
[TBL] [Abstract][Full Text] [Related]
25. The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation.
Amin SA; Baine MJ; Rahman I; Lin C
J Immunother; 2023 Jan; 46(1):14-21. PubMed ID: 36256124
[TBL] [Abstract][Full Text] [Related]
26. Role of immunotherapy in stage III nonsmall cell lung cancer.
Wrona A
Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
[TBL] [Abstract][Full Text] [Related]
27. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
28. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
[TBL] [Abstract][Full Text] [Related]
29. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
[TBL] [Abstract][Full Text] [Related]
30. Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
Hellyer JA; Aredo JV; Das M; Ramchandran K; Padda SK; Neal JW; Wakelee HA
J Thorac Oncol; 2021 May; 16(5):868-872. PubMed ID: 33539970
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL
Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075
[TBL] [Abstract][Full Text] [Related]
32. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
Davies M; Duffield E
Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
[TBL] [Abstract][Full Text] [Related]
33. The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.
Matsuura S; Serizawa S; Yamashita R; Morikawa K; Ito Y; Hiramatsu T; Mochizuki E; Tanaka K; Akiyama N; Tsukui M; Koshimizu N; Kosugi T
Ann Med; 2023 Dec; 55(1):2196089. PubMed ID: 37043179
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
Shaverdian N; Offin M; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Hellmann MD; Rimner A; Paik PK; Chaft JE; Gomez DR
J Thorac Oncol; 2021 Aug; 16(8):1392-1402. PubMed ID: 33992811
[TBL] [Abstract][Full Text] [Related]
35. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
[TBL] [Abstract][Full Text] [Related]
36. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.
Cheema PK; Rothenstein J; Melosky B; Brade A; Hirsh V
Curr Oncol; 2019 Feb; 26(1):37-42. PubMed ID: 30853796
[TBL] [Abstract][Full Text] [Related]
37. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy.
Sun L; Aggarwal C
Cancer J; 2020; 26(6):548-554. PubMed ID: 33298727
[TBL] [Abstract][Full Text] [Related]
39. Identification of predictive factors for early relapse in patients with unresectable stage III non-small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy.
Nam JH; Yeo CD; Park CK; Kim SK; Kim JS; Kim YH; Kim JW; Kim SJ; Lee SH; Kang HS
Thorac Cancer; 2023 Sep; 14(26):2657-2664. PubMed ID: 37519059
[TBL] [Abstract][Full Text] [Related]
40. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.
Ouwens M; Darilay A; Zhang Y; Mukhopadhyay P; Mann H; Ryan J; Dennis PA
Curr Ther Res Clin Exp; 2021; 95():100640. PubMed ID: 34484473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
